Relay Therapeutics, Inc.
RLAYNasdaq
$19.91
↑ +2.8%Jul 17 close · end-of-day
Price
1Y↑ +447.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$10.7M
Net Income (TTM)
-$272.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-2776.9%
Net Margin
-2554.4%
ROE
-42.5%
ROIC
-53.5%
Debt / Equity
—
Net Cash
$204.6M
Return 1Y
+445.5%
Company profile
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial.
- CEO
- Sanjiv K. Patel
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 330
- Headquarters
- Massachusetts
- Website
- relaytx.com
Management & directors
- Patel SanjivPresident and CEO
- Bergstrom Donald APresident, R&D
- Catinazzo ThomasChief Financial Officer
- Rahmer PeterSee remarks
- Adams BrianChief Legal Officer
Roles derived from SEC Form 4 filings.
Earnings
RLAY Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.0M↓ -60.9%
Diluted EPS-$0.41↓ -10.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $82.7M | $3.0M | $1.4M | $25.5M | $10.0M | $15.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$55.8M | -$364.7M | -$299.3M | -$373.0M | -$372.5M | -$302.7M |
| Net income | -$52.4M | -$363.9M | -$290.5M | -$342.0M | -$337.7M | -$276.5M |
| Diluted EPS | -$5.40 | -$3.82 | -$2.59 | -$2.79 | -$2.36 | -$1.61 |
| Operating cash flow | -$102.5M | -$74.4M | -$229.5M | -$300.3M | -$249.1M | -$235.5M |
| Free cash flow | -$104.4M | -$77.9M | -$238.6M | -$304.4M | -$251.1M | -$235.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -67.5% | -12040.2% | -21670.9% | -1460.1% | -3722.1% | -1971.6% |
| Net margin | -63.4% | -12012.9% | -21036.1% | -1338.7% | -3374.7% | -1800.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $7.7M | $677,000.00 | $0.00 | $7.0M | $3.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$100.8M | -$96.4M | -$85.0M | -$84.9M | -$76.8M | -$80.4M | -$60.6M | -$78.6M |
| Net income | -$92.2M | -$88.1M | -$76.0M | -$77.1M | -$70.4M | -$74.1M | -$54.9M | -$73.3M |
| Diluted EPS | -$0.69 | -$0.63 | -$0.42 | -$0.46 | -$0.41 | -$0.43 | -$0.31 | -$0.41 |
| Operating cash flow | -$65.8M | -$75.1M | -$57.9M | -$73.2M | -$55.3M | -$62.1M | -$44.9M | -$51.1M |
| Free cash flow | -$65.8M | -$75.3M | -$57.9M | -$73.6M | -$55.3M | -$62.1M | -$44.9M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | -1105.2% | -11351.1% | — | -866.3% | -2619.7% |
| Net margin | — | — | — | -1003.6% | -10395.1% | — | -784.3% | -2443.0% |
Company news
Jun 30, 2026
Jun 11, 2026
May 27, 2026
May 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | Patel Sanjiv· President and CEO | Sale | 48,199 | $19.58 | $943,736.42 | filing |
| 2026-07-06 | Catinazzo Thomas· Chief Financial Officer | Sale | 17,717 | $18.69 | $331,130.73 | filing |
| 2026-07-06 | Bergstrom Donald A· President, R&D | Sale | 8,660 | $18.71 | $162,028.60 | filing |
| 2026-06-30 | Rahmer Peter· See remarks | Sale | 50,000 | $19.09 | $954,500.00 | filing |
| 2026-06-30 | Patel Sanjiv· President and CEO | Award | 3,056 | $6.95 | $21,239.20 | filing |
| 2026-06-30 | Rahmer Peter· See remarks | Award | 3,056 | $6.95 | $21,239.20 | filing |
| 2026-06-22 | Bergstrom Donald A· President, R&D | Sale | 93,456 | $16.94 | $1.6M | filing |
| 2026-06-22 | Catinazzo Thomas· Chief Financial Officer | Sale | 61,563 | $16.97 | $1.0M | filing |
| 2026-06-22 | Catinazzo Thomas· Chief Financial Officer | Sale | 56,323 | $16.97 | $955,801.31 | filing |
| 2026-06-22 | Catinazzo Thomas· Chief Financial Officer | Sale | 51,560 | $16.97 | $874,973.20 | filing |
| 2026-06-22 | Bergstrom Donald A· President, R&D | Option exercise | 93,456 | $4.12 | $385,038.72 | filing |
| 2026-06-22 | Catinazzo Thomas· Chief Financial Officer | Option exercise | 61,563 | $5.22 | $321,358.86 | filing |
| 2026-06-22 | Catinazzo Thomas· Chief Financial Officer | Sale | 17,717 | $17.01 | $301,366.17 | filing |
| 2026-06-22 | Catinazzo Thomas· Chief Financial Officer | Option exercise | 56,323 | $5.04 | $283,867.92 | filing |
| 2026-06-22 | Catinazzo Thomas· Chief Financial Officer | Option exercise | 51,560 | $4.45 | $229,442.00 | filing |
| 2026-05-14 | Catinazzo Thomas· Chief Financial Officer | Sale | 17,717 | $12.86 | $227,840.62 | filing |
| 2026-04-28 | Bergstrom Donald A· President, R&D | Sale | 1,490 | $14.79 | $22,037.10 | filing |
| 2026-04-28 | Catinazzo Thomas· Chief Financial Officer | Sale | 972 | $14.79 | $14,375.88 | filing |
| 2026-04-28 | Rahmer Peter· See remarks | Sale | 753 | $14.79 | $11,136.87 | filing |
| 2026-04-09 | Catinazzo Thomas· Chief Financial Officer | Sale | 1,800 | $15.00 | $27,000.00 | filing |
| 2026-04-09 | Catinazzo Thomas· Chief Financial Officer | Option exercise | 1,800 | $5.22 | $9,396.00 | filing |
| 2026-04-07 | Catinazzo Thomas· Chief Financial Officer | Sale | 17,717 | $13.01 | $230,498.17 | filing |
| 2026-03-09 | Catinazzo Thomas· Chief Financial Officer | Sale | 17,717 | $10.06 | $178,233.02 | filing |
| 2026-01-28 | Bergstrom Donald A· President, R&D | Sale | 2,686 | $8.45 | $22,696.70 | filing |
| 2026-01-28 | Catinazzo Thomas· Chief Financial Officer | Sale | 1,695 | $8.45 | $14,322.75 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.